Immunomedics Inc (IMMU)

5.34
NASDAQ : Health Care
Prev Close 5.12
Day Low/High 5.01 / 5.58
52 Wk Low/High 1.91 / 5.89
Avg Volume 2.97M
Exchange NASDAQ
Shares Outstanding 106.08M
Market Cap 543.13M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Immunomedics Comments On Baseless VenBio Lawsuit

Immunomedics Comments On Baseless VenBio Lawsuit

venBio's Lawsuit Underscores its Blatantly Self-Serving Agenda and Willingness to Potentially Destroy Stockholder Value for the Sake of Control

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.

VenBio Takes Steps To Protect Rights Of Immunomedics Stockholders

VenBio Takes Steps To Protect Rights Of Immunomedics Stockholders

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

VenBio accuses Immunomedics management of undervaluing and essentially giving away the cancer drug IMMU-132 because they were afraid of losing their jobs in a proxy vote.

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Jim Cramer's bullish on ZELTIQ Aesthetics, Chesapeake Energy, Priceline Group and more.

Why These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' Recap (Monday 2/13/17)

Why These Market Gains Are More Powerful Than Trump: Cramer's 'Mad Money' Recap (Monday 2/13/17)

Jim Cramer says it's a sea change: It's not just about economic growth, it's about global growth without inflation.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

VenBio Comments On Immunomedics Partnership Announcement

VenBio Comments On Immunomedics Partnership Announcement

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Immunomedics Announces Postponement Of 2016 Annual Meeting

Immunomedics Announces Postponement Of 2016 Annual Meeting

New Meeting Date Provides Time for Modified "Go-Shop" Period Negotiated in Global Licensing Agreement of IMMU-132 with Seattle Genetics to Have Expired or Otherwise Been Completed and Allows Stockholders to Carefully Consider the Significant Value Created by the Licensing Transaction

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics to Receive $250 Million in Upfront Cash Payment; Plus Among Other Milestone Payments, an Additional $50 Million or Negotiated Economic Splits Relating to Rights Outside US, Canada and EU

Glass Lewis Endorses Full Slate Of VenBio Nominees At Immunomedics

Glass Lewis Endorses Full Slate Of VenBio Nominees At Immunomedics

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

ISS Endorses Full Slate Of VenBio Nominees At Immunomedics

ISS Endorses Full Slate Of VenBio Nominees At Immunomedics

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

VenBio Calls On Immunomedics Stockholders To Support Meaningful Change

VenBio Calls On Immunomedics Stockholders To Support Meaningful Change

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.

Immunomedics Shares Ride Roller Coaster on Whether It's for Sale

Immunomedics Shares Ride Roller Coaster on Whether It's for Sale

The company is rumored to be up for sale.

VenBio Releases Presentation Detailing Urgent Case For Change At Immunomedics

VenBio Releases Presentation Detailing Urgent Case For Change At Immunomedics

venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.

The Sale of Immunomedics Hinges on This

The Sale of Immunomedics Hinges on This

Immunomedics has been for sale for quite some time, but there hasn't been any interest in it. Here's why.

Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder

Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder

An activist investor believes a buyer for a promising breast cancer drug can be found if Immunomedics' Chairman David Goldenberg is forced out.

First Week of IMMU March 17th Options Trading

First Week of IMMU March 17th Options Trading

Investors in Immunomedics, Inc. saw new options become available this week, for the March 17th expiration.